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ABSTRACT
OBJECTIVE: Estimate the prevalence of cervical HPV infection among women assisted by the 
Family Health Strategy and identify the factors related to the infection. 
METHODS: A cross-sectional study involving 2,076 women aged 20–59 years old residing in Juiz 
de Fora, State of Minas Gerais, who were asked to participate in an organized screening carried 
out in units were the Family Health Strategy had been implemented. Participants answered 
the standardized questionnaire and underwent a conventional cervical cytology test and HPV 
test for high oncogenic risk. Estimates of HPV infection prevalence were calculated according 
to selected characteristics referenced in the literature and related to socioeconomic status, 
reproductive health and lifestyle.
RESULTS: The overall prevalence of HPV infection was 12.6% (95%CI 11.16–14.05). The prevalence 
for the pooled primer contained 12 oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
and 68) was 8.6% (95%CI 7.3–9.77). In the multivariate analysis, it was observed that the following 
variables were significantly associated with a higher prevalence of HPV infection: marital status 
(single: adjusted PR = 1.40, 95%CI 1.07–1.8), alcohol consumption (any lifetime frequency: adjusted 
PR = 1.44, 95%CI 1.11–1.86) and number of lifetime sexual partners (≥ 3: adjusted PR = 1.35, 
95%CI 1.04–1.74). 
CONCLUSIONS: The prevalence of HPV infection in the study population ranges from average 
to particularly high among young women. The prevalence of HPV16 and HPV18 infection is similar 
to the worldwide prevalence. Homogeneous distribution among the pooled primer types would 
precede the isolated infection by HPV18 in magnitude, which may be a difference greater than 
the one observed. The identification of high-risk oncogenic HPV prevalence may help identify 
women at higher risk of developing preneoplastic lesions. 
DESCRIPTORS: Papillomaviridae. Prevalence. Mass Screening. Uterine Cervical Neoplasms, 
prevention & control. Family Health Strategy.
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INTRODUCTION
Human papillomavirus (HPV) infection is one of the most common genital infections in 
the world and is a necessary cause for cervical cancer10. In Brazil, it is estimated that 15,590 
women develop the disease each year, with a gross incidence rate of 15.33/100,000, which 
makes prevention and control of cervical cancer a priority in the health management pacts 
aimed at women’s health9. 
The global strategy is the screening of pre-invasive lesions with a cervical cytological 
examination by smear exam. In developing countries, the impact of introducing and 
scaling up the screening as a health policy was lower than in developed countries, due to 
poor organization, poor coverage, and lack of quality assurance21. In the fastest-developing 
countries of South America, there was a decline in cervical cancer mortality, with estimates 
of the annual percentage change ranging from -1.4 to -6.3 between 1983 and 200229. In Latin 
America, this tendency occurs in countries with higher average incomes, such as Argentina 
and Uruguay, and in countries with a history of implementing more organized screening, such 
as Mexico, Colombia, Chile, and Costa Rica, where mortality rates were reduced almost in half, 
causing an inversion in the in situ/invasive cancer ratio19. In Brazil, there has been an overall 
decline in cervical cancer mortality rates in the last few decades, but heterogeneously in the 
different macro-regions (annual percentage changes range from -3.3 to 1.7), showing partial 
success12. The limitations of screening include poorer access mainly among low-income 
women, the difficulty of following-up women’s examination in a centralized registration 
system, and the recruitment of women is performed in an unorganized way that does not 
follow the periodicity recommendation22. 
These failures motivated the search for alternative techniques (associated or substitute) that 
would contribute to the reduction of losses and more accurate identification of women with 
HPV types with higher oncogenic risk. Molecular biology techniques have contributed to 
understanding genital HPV infection in different settings, and are used in scientific research since 
the beginning of the 1980s, but only recently have been incorporated into the health services5,30,31. 
In Brazil, the identification of HPV-infected women is based on heterogeneous studies and, 
therefore, is of difficult comparability and limited reproducibility since estimates made from 
studies that consider referenced women may result in overestimated measures2. Prevalence 
estimates and factors associated with HPV infection make it possible to understand why 
certain groups of women are more vulnerable than others in order to make proposals for 
specific prevention actions for such groups. These proposals seek to increase the effectiveness of 
primary and secondary cervical cancer prevention. This type of cancer is an avoidable disease14. 
Thus, the objective of the present study was to estimate the prevalence and risk factors for HPV 
infection among women residing in the coverage area of the Family Health Strategy (FHS). 
METHODS 
A cross-sectional study was carried out with a population of residents of an area attached 
to the two units of the Family Health Strategy located on the outskirts of the city of Juiz de 
Fora, state of Minas Gerais. All women residing in the FHS coverage area between 20 and 
59 years old, asymptomatic, were considered eligible. Pregnant women, those who were 
immunocompromised or had been previously submitted to uterus excision procedures 
(hysterectomy, conization) were excluded. Approximately 3,500 women were recruited in 
their homes by community health agents to undergo the preventive examination in the 
proposed area as a programmatic action developed by the family health units, with an 
emphasis on the organized screening of absences through the FHS register. 
Data were collected from September 2010 to August 2012. Study participants were interviewed 
by trained health professionals, using a standardized questionnaire adapted from the National 
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Health Survey, applied in the Federal District in 2010 and improved from 2013 onwards 
through the partnership between the Oswaldo Cruz Foundation and the Brazilian Institute of 
Geography and Statistic. The final instrument encompassed question groups distributed in 
nine modules: identification, sociodemographic characteristics, social support, self-assessment 
of health status, lifestyle, morbidity, women’s health, sexual behavior, and sexually transmitted 
infections. These data were measured. The instrument, its detailing, and the definition of each 
category used are available for consultation. Anthropometric data and morbidity data (blood 
pressure) were measured, and the results of exams refer to reports presented by participants6. 
The women were then submitted to conventional cervical cytology examination at the 
primary health units, while simultaneously being tested for HPV infection, and the samples 
were collected by the nurses and trained physicians working in the units. 
HPV testing was performed at the Laboratory of Virology of the Institute of Tropical Medicine 
of the Universidade de São Paulo. The uterine cervix samples were preserved in a PreservCyt 
solution and analyzed by the Polymerase Chain Reaction (PCR) method using the HPV-HR 
test + GT 16/18 test on the cobas 4800 HPV Test® automated platform (Roche Molecular 
Systems, Inc., Branchburg, New Jersey, USA), which uses primers to amplify the DNA of 
14 high-risk HPV types: HPV16, HPV18 and a pooled primer with 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, e 68 HR-HPV. Negative results were those specimens in which there was no 
amplification of viral DNA and positive ones were those in which there was an amplification 
of the viral DNA corresponding to the test primers. The procedures for analyzing the sample 
quality occurred according to pre-established protocols adopted by the executing Laboratory. 
In the study period, 2,076 eligible women, approximately 60% of the population of women 
residing in the areas assigned to the FHS, answered to the recruitment, attended the FHS units 
and were included in the study. Due to reading problems, it was not possible to obtain HPV test 
results for 54 women (2.6%), because 40 samples had invalid results and 14 had inconclusive 
results. Thus, the study population had 2,022 women. In one of the health units, the number 
of women studied was almost twice the one obtained in the other unit, maintaining the 
proportionality of the size of the populations assigned to these two units. 
We performed a univariate analysis of the data, and the absolute and relative frequencies were 
calculated for the nominal categorical variables, according to the family health unit. Then, 
the bivariate analysis was performed parallel to the comparison of the basic characteristics 
between the groups, using the chi-square test for proportions, which were considered significant 
if p ≤ 0.20. We measured the HPV infection prevalence, general and stratified according to 
selected variables with respective 95% confidence intervals (95%CI) and p value. 
To evaluate the factors related to the infection, identified as the positive result for the HPV 
test, variables were selected according to epidemiological criteria and biological plausibility. 
Included in the study were characteristics related to: age, schooling, skin color, per capita 
family income, health evaluation, lifestyle (alcohol consumption, current and previous 
smoking), reproductive history (age at menarche, use of contraceptive methods, preventive 
screening, parity) and sexual behavior (age at sexarche, number of sexual partners throughout 
life, history of sexually transmitted infections). The variable categories were defined according 
to classic literature references, selected in the development of the questionnaire. The variable 
per capita income was categorized based on the minimum wage values at the time of the 
study (R$603.31, which was approximated to R$600.00). This way, low income corresponded 
to values below 50% of the minimum wage, average income corresponded to values between 
50% and 100% minimum wage and high income was more than one minimum wage. The 
total income of the family, including all residents of the household, was considered. 
Gross and adjusted prevalence ratios were calculated using Poisson regression with robust 
variance and respective 95% confidence intervals. The variables that in the bivariate analysis 
had p ≤ 0.20 were selected for the final model, which, in addition, included the age group 
and health unit of the family in which the woman resided and was assisted. All analyses 
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Table 1. Sociodemographic characteristics, housing conditions, health self-assessment, lifestyle, 
reproductive health and sexual behavior among women living in the coverage area of the Family Health 
Strategy. Juiz de Fora, State of Minas Gerais, 2010–2012. 
Variable Category
Unit I Unit II Total
n % n % na %
Age group (years) 20–24 151 11.6 107 13.9 258 12.5
25–29 181 14.0 98 12.8 279 13.5
30–34 179 13.8 124 16.2 303 14.7
35–39 175 13.5 105 13.7 280 13.6
40–44 167 12.9 107 13.9 274 13.3
45–49 157 12.1 89 11.6 246 11.9
50–54 149 11.5 73 9.5 222 10.8
55–59 136 10.5 64 8.3 200 9.7
Marital status Single 296 22.9 132 17.2 428 20.8
Had a partner 998 77.1 635 82.8 1,633 79.2
Years of study < 1 8 0.6 13 1.7 21 1.0
1–3 89 6.9 50 6.6 139 6.8
4–7 474 36.9 298 39.4 772 37.8
8–10 257 20.0 167 22.1 424 20.8
> 11 456 35.5 228 30.1 684 33.5
Skin color White 628 48.5 342 44.6 970 47.0
Non-white 667 51.5 425 55.4 1,092 53.0
Religious practice Yes 1,260 99.1 728 96.8 1,988 98.3
No 11 0.9 24 3.2 35 1.7
Per capita income Low 478 36.9 299 39.0 777 37.7
Medium 771 59.5 443 57.8 1,214 28.9
High 46 3.5 25 3.3 71 7.4
Piped water General network 1,283 99.5 748 97.5 2,031 98.7
Other 7 0.5 19 2.5 26 1.3
Waste destination Regular waste collection 1,286 99.5 753 98.2 2,039 99.0
Others 7 0.54 14 1.8 21 1.0
Outlet Sewerage system 1,266 97.8 700 91.3 1,966 95.3
Others 29 2.2 67 8.7 96 4.7
Health assessment Poor to regular 525 40.7 336 43.8 861 41.9
Good to very good 764 59.3 431 56.2 1,195 58.1
Alcohol consumption No 698 53.9 481 62.7 1,179 57.2
Yes 597 46.1 286 37.3 883 42.8
Current smoker No 986 77.2 616 80.4 1,602 78.4
Yes 291 22.8 150 19.6 441 21.6
Former smoker No 728 71.0 459 72.6 1,187 71.6
Yes 298 29.0 173 27.4 471 28.7
Age at menarche ≤ 12 years 589 46.2 316 42.1 905 44.6
≤ 13 years 687 53.8 435 57.9 1,122 55.3
Examination 3 years ago, or less 1,016 78.5 585 76.3 1,601 77.7
Pap smear Delayedb/Never had 278 21.5 182 23.7 460 22.3
Contraception Any method 872 67.6 536 69.9 1,408 68.4
No method 418 32.4 231 30.1 649 31.4
Nulliparity No 1,134 87.6 669 87.3 1,803 87.5
Yes 161 12.4 97 12.7 258 12.5
Age at sexarche experience ≥ 16 years 278 21.6 170 22.7 448 22.0
≤ 15 years 1,008 78.4 580 77.3 1,588 78.0
Sexual partnersc Up to 3 903 73.1 530 72.3 1,433 72.8
Over 3 333 26.9 203 27.7 536 27.2
Syphilis testing Negative 635 98.3 315 98.4 950 98.3
Positive 11 1.7 5 1.6 16 1.7
HIV testing Negative 825 99.6 456 98.9 1,281 99.4
Positive 3 0.4 5 1.1 8 0.6
a Total of women with HPV test results and valid information about the variable. 
b Cervical cytology test performed more than three years ago. 
c Throughout life. 
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were performed using the statistical software Stata, version 12 (Data Analysis and Statistic 
Software, StataCorp LP, College Station, Texas, USA). 
The project was approved by the Ethics Committee of the Institute of Social Medicine of 
the Universidade do Estado do Rio de Janeiro (Position 0026.1.259.180-09), following all the 
proposed recommendations. All the women included in the study did so by reading and 
signing the informed consent form, ensuring the confidentiality of the data and the privacy 
of the women participating in all the stages of the study. 
RESULTS 
The sociodemographic characteristics, as well as those related to the self-assessment of health, 
lifestyle, reproductive health and sexual behavior of the women studied, are described in Table 1. 
The overall prevalence of infection by at least one high-risk type of HPV among women 
of both FHS units was 12.6% (95%CI 11.16–14.05). The prevalence of infection by at least 
one type of HPV-AR, except HPV16 and HPV18 (pooled primer with 12 types) was 8.6% 
(95%CI 7.30–9.77), while the prevalence of HPV infection by HPV 16 and 18 was 1.8% (95%CI 
1.20–2.35) and 0.5% (95%CI 0.22–0.86), respectively. The prevalence of coinfection by HPV16 
or HPV18 and at least one of the 12 types of pooled primer (31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66, and 68) was equal to 1.7% (95%CI 1.16–2.29) (Figure). 
The prevalence of HPV infection according to selected independent variables is shown 
in Table 2. In the bivariate analysis, the following variables were associated with higher 
prevalence of HPV infection: marital status (single: PR = 2.26, 95%CI 1.79–2.84), age range 
(20–24 years: PR = 5.34, 95%CI 3.65–7.79), education (completed middle school: PR = 2.26, 
95%CI 1.79–2.84), health assessment (good to very good: PR = 1.40, 95%CI 1.10–1.79), 
alcohol consumption (any frequency: PR = 1.89, 95%CI 1.49–2.38) smoker (current: PR = 1.36, 
95%CI 1.05–1.76), use of contraceptive (any method: PR = 1.68, 95%CI 1.26–2.23), nulliparity 
(PR = 2.04, 95% CI 1.57–2.66), age at sexarche ≤ 15 years old (PR = 1.49, 95%CI 1.17–1.92) and 
sexual partners throughout life (number ≥ 3: PR = 1.84, 95%CI 1.45–2.33). 
In the multivariate analysis, the following variables remained significantly related to 
HPV infection: single (PR = 1.40, 95%CI 1.07–1.84), alcohol consumption at any frequency 
(RR = 1.44, 95%CI, 1.11–1.86) and had three or more sexual partners throughout life (PR = 1.35, 
95%CI 1.04–1.74) (Table 3).
Figure. Prevalence of infection by types of HPV according to studied women age groups. Juiz de Fora, 
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Table 2. Prevalence and gross prevalence ratio of HPV infection according to variables selected among women residing in the coverage 
area of the Family Health Strategy. Juiz de Fora, State of Minas Gerais, 2010–2012. 
Variable Categories Total*
HPV+
Gross PR* 95%CI p
n % 95%CI
Age group (years) 20–24 246 70 28.4 22.90–34.53 5.34 3.65–7.79 < 0.001
25–34 575 112 19.5 16.31–22.95 3.65 2.54–5.25 < 0.001
35–44 544 38 7.0 4.99–9.46 1.31 0.84–2.03 0.233
45–59 657 35 5.3 3.73–7.33 1 - -
Total 2,022 255 12.6 11.19–14.13
Marital status Had partner 1,601 160 10.0 8.56–11.56 1 - -
Single 420 95 22.6 18.70–26.92 2.26 1.79–2.84 < 0.001
Middle school Incomplete 914 73 8.0 6.31–9.93 1 - -
Complete 1,086 179 16.5 14.32–18.82 2.06 1.59–2.67 < 0.001
Skin color White 951 115 12.1 10.08–14.33 1 - -
Non-white 1,071 140 13.17 11.10–15.23 1.08 0.85–1.36 0.508
Low family income No 1,263 155 12.3 10.51–14.20 1 - -
Yes 759 100 13.2 10.84–15.79 1.07 0.84–1.35 0.553
Health assessment Very poor to regular 842 86 10.2 8.55–12.45 1 - -
Good to very good 1,174 169 14.4 12.53–16.43 1.40 1.10–1.79 0.006
Alcohol consumption No (never) 1,152 105 9.1 7.51–10.92 1 - -
Yes 870 150 17.2 14.78–19.91 1.89 1.49–2.38 < 0.001
Current smoker No 1,569 183 11.7 10.11–13.35 1 - -
Yes 434 69 15.9 12.58–19.68 1.36 1.05–1.76 0.018
Former smoker Yes 465 50 10.7 8.08–13.92 1 - -
No 1,160 142 12.2 10.40–14.26 1.13 0.84–1.54 0.403
Menarche ≤ 12 years Yes 888 107 12.0 9.98–14.37 1 - -
No 1,099 142 12.9 10.99–15.04 1.07 0.84–1.35 0.560
Late pap smear No 1,574 202 12.8 11.21–14.58 1 - -
Yes 447 53 11.8 9.00–15.22 0.92 0.69–1.22 0.585
Uses contraceptives No 638 55 8.6 6.56–11.07 1 - -
Yes 1,379 200 14.5 12.68–16.47 1.68 1.26–2.23 < 0.001
Previous pregnancy Yes 1,772 198 11.2 9.74–12.73 1 - -
No 249 57 22.9 17.82–28.61 2.04 1.57–2.66 < 0.001
Sexarche at ≤ 15 years No 1,559 178 11.4 9.88–13.10 1 - -
Yes 438 75 17.1 13.71–20.98 1.49 1.17–1.92 0.001
Up to 3 sexual partners Yes 1,400 142 10.1 8.61–11.84 1 - -
No 530 99 18.7 15.44–22.26 1.84 1.45–2.33 < 0.001
Test - positive for syphilis No 935 138 14.7 12.54–17.19 1 - -
Yes 16 1 6.2 1.58–30.23 0.42 0.63–2.84 0.377
Test - HIV positive No 175 1,258 13.9 12.04–15.94 1 - -
Yes 1 8 12.5 3.15–52.65 0.89 0.14–5.65 0.909
* Total of women with HPV test results and valid information about the variable.
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DISCUSSION 
The prevalence of cervical HPV infection in women assisted by the Family Health Strategy was 
12.6%. This measure is close to the prevalence (12.8%) observed by Girianelli et al. (2010) in a 
study with the household recruitment of low-income women living in the municipalities of 
Baixada Fluminense, Rio de Janeiro, which used the hybrid capture technique to detect HPV. 
Although the PCR technique will present higher prevalence estimates than those obtained 
using the hybrid capture technique, the measures obtained in the study by Girianelli et al. 
(2010) resulted from the inclusion of women who had not received preventive examination 
for more than three years, while the present study considered data from all the women in 
the target population to be screened11,13. 
The target population women’s attendance to the cervical cancer screening in FHS units 
participating in the present study was lower than expected (60%). It was expected that, as an 
action started with household recruitment and appointment scheduling at the health unit, 
women’s demand would be higher. Reduced adherence to screening reflects the behavior 
observed in other Brazilian studies and may have influenced the estimates observed for the 
group. This shows that, even in organized screening, there seem to be factors that influence 
the response to recruitment, resulting in partial adherence15. It should be considered that 
some women who did not come to the unit may have undergone the preventive examination 
in services outside the SUS because they have a health plan or even because they paid for the 
examination in private service. This limitation, however, does not necessarily compromise 
the representativeness of the findings of the geographical area since there seems to be minor 
variation in socioeconomic status among resident women. 
Regarding losses in HPV testing, despite periodic training and supervision, there were failures 
in capturing HPV typing and detection and cytology results, with no significant impact on 
Table 3. Raw and adjusted HPV infection prevalence ratios for selected variables among women residing 








Age group (years) 45–59 1 - - 1 -
35–44 1.31 0.84–2.03 0.233 1.08 0.67–1.74
25–34 3.65 2.54–5.25 < 0.001 2.66 1.74–4.07
20–24 5.34 3.65–7.79 < 0.001 3.59 2.23–5.78
Marital status Married (lifetime) 1 - - 1 -
Single (lifetime) 2.26 1.79–2.84 < 0.001 1.40 1.07–1.84
Middle school Incomplete 1 - - 1 -
Complete 2.06 1.59–2.67 < 0.001 1.11 0.82–1.50
Health assessment Very poor to regular 1 - - 1 -
Good to very good 1.40 1.10–1.79 0.006 1.15 0.90–1.48
Alcohol consumption No (never) 1 - - 1 -
Yes 1.89 1.49–2.38 < 0.001 1.44 1.11–1.86
Current smoker No 1 - - 1 -
Yes 1.36 1.05–1.76 0.018 1.23 0.92–1.64
Contraception No method 1 - - 1 -
Any method 1.68 1.26–2.23 < 0.001 1.01 0.75–1.36
Nulliparity No 1 - - 1 -
Yes 2.04 1.57–2.66 < 0.001 1.11 0.80–1.55
Age at sexarche ≥16 years 1 - - 1 -
≤ 15 years 1.49 1.17–1.92 0.001 0.95 0.72–1.26
Number of sexual 
partners
Up to 3 (lifetime) 1 - - 1 -
Over 3 (lifetime) 1.84 1.45–2.33 < 0.001 1.35 1.04–1.74
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the analysis of results. Such losses were somewhat predicted, considering that the study was 
operationalized through the health service. 
The results concerning the circulating types of HPV in the present study were discordant of 
some studies that evaluated the prevalence of HPV among Brazilian women16. The prevalence 
of infection by types 16 and 18 is similar to the world prevalence, with HPV16 infection being 
the most frequent, either isolated or in coinfections, followed by isolated HPV18 infection 
alone, suggesting a lower prevalence than the types contained in the HPV high-risk pooled 
primer4. It was not possible to identify which types would succeed them virtually in the 
ecological niche since the pooled primer used included only 12 types of high-risk HPV. 
However, the prevalence of infection by the types contained in this primer was approximately 
five times greater than the prevalence of isolated infection by HPV16. Assuming a hypothetical 
homogeneous distribution between the primer types, this prevalence can be interpreted in 
a preliminary way as a prevalence of 0.71% for each type, preceding the infection isolated 
by HPV18 in magnitude and relevance. As this homogeneous distribution certainly does 
not occur, the difference in prevalence between certain types of high-risk HPV and HPV18 
may be even greater. 
The prevalence of cervical infection by HPV varies from medium to high, especially among 
young women, who initiate sexual activity with a risk of exposure to oncogenic types. The 
incorporation of HPV testing in the screened women would have the advantage of increasing 
the follow-up interval, with HPV-positive women having a cytological examination, whereas 
HPV-negative women would only need five-year intervals, two years longer than recommended 
for follow-up with a cytological examination after two years with normal results5,20. 
The prevalence of HPV infection in Brazilian studies performed with women recruited 
from health units appears to be considerably higher than the prevalence observed in 
population-based studies. In the latter, the possibilities of selection bias and consequent 
overestimation of prevalence estimates are practically eliminated, since the studied 
population does not only include women who were assisted by, or referenced to, health 
services for being symptomatic. 
Regarding the factors related to cervical HPV infection observed, marital status (single), 
alcohol consumption (any frequency), and the number of lifetime sexual partners (three 
or more) remained as independent predictors of HPV infection, even after adjustment for 
other variables. These findings confirm the results of other studies that also related the risk 
of HPV infection to marital status, abusive alcohol consumption and the sexual history of 
the women1,3,7,8,11,18,23-25,27. We did not investigate the association between having extramarital 
relationships or having partners with extramarital relationships and the prevalence of HPV 
infection, a factor that has been associated with the prevalence of infection in some studies. 
Self-assessment of health status, smoking, contraceptive use, parity and age at sexarche did 
not remain as independent predictors of HPV infection in the final model. Vaccarella et al. 
(2006) also found no statistically significant association between HPV infection and parity, 
prolonged use of oral contraceptives or use of condoms by the sexual partner and age at 
sexarche26,27. Smoking has been identified as a factor associated with the persistence and 
onset of the neoplasia, but not with the risk of infection and its association with HPV 
infection has been ruled out28. 
It should be noted that the prevalence of infection in the different age groups is close to 
that estimated in similar studies, with the highest proportion of infected women found 
between 25 and 34 years of age, which is also the age group with the highest incidence of 
in situ carcinoma17,18,25. 
Thus, the prevalence of infection among the studied women is similar to that found in other 
Brazilian studies, being higher among younger women. Independent predictors of HPV 
infection – marital status, alcohol consumption, and the number of lifetime sexual partners – 
are highly influenced by economic, cultural, and social issues. Further studies are needed 
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to understand if the relationship between the factors associated with increased prevalence 
of HPV infection changes when analyzed against the incidence of pre-invasive and invasive 
cervical cancer lesions among these women to verify whether predictive factors would be 
the same in a population of women with carcinoma (in situ or invasive). 
Organized screening, an alternative to opportunistic screening, provides for the capture of 
women in the target age groups, while at the same time not unnecessarily repeating the pap 
smear. However, factors related to non-adherence to the exam within the recommended 
periodicity need to be recognized and become the target of intervention, since the simple 
change in the recruitment strategy does not guarantee that the woman will attend the 
health unit for examination. Testing for HPV, as well as screening, would perform better on 
an organized, non-opportunistic screening system. 
Testing for HPV should be evaluated economically for its implementation to be recommended. 
As a technology to be incorporated into the screening, it requires team training and strict 
logistic supervision to avoid contamination of negative samples or cross-contamination 
by types between samples. It is necessary to adopt methods based on polymerase chain 
reaction that recognize each type of HPV in the prevalence of infection among the women 
of the different regions of the country. The higher sensitivity and lower specificity of the 
HPV-DNA test compared to screening with conventional cytology could overload secondary 
care referrals. The impact of this increase in positivity on services needs to be evaluated, 
including its cost-effectiveness ratio. On the other hand, a change in the age range of women 
screened and the use of the examination in regions of restricted access to health units 
would benefit women living with unequal access to cervical cancer prevention, identifying 
women at higher risk for acquisition and persistence of the infection and, consequently, 
for the evolution of preneoplastic lesions. The ethical implications of HPV testing need to 
be considered, and the psychological impact judged carefully, since women who have HPV 
infection are not ill, and it may be hard to understand this condition. Screening provides 
an overview of the HPV infection prevalence at a time when circulatory type surveillance is 
needed, including ecological niche filling, subsequent to vaccine implantation against types 
16 and 18, and this action can be viewed as an effort within priorities of policies aimed at 
the control of cervical cancer and, therefore, at women’s health. 
In general, actions that focus on the social determinants of health, course approach, quality 
of life, and lifestyle promote improvements that are essential to modifying exposure to 
risk factors related to HPV infection, as well as to many other exposures, diseases, and 
aggravations. Gender-related issues and their vulnerabilities should guide the planning of 
educational actions among women, permeating prevention and control of injuries even 
before sexual activity begins. The health sector must work in an integrated manner with 
other sectors to ensure that inequalities in access to skilled services and information on 
women’s health are overcome and to identify opportunities for integration. The search for a 
solution to these problems will not be complete without dialogue between epidemiological 
research and health service, in a mutually beneficial process, where the most favored will 
certainly be the female population. 
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